JP2004507480A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004507480A5 JP2004507480A5 JP2002522827A JP2002522827A JP2004507480A5 JP 2004507480 A5 JP2004507480 A5 JP 2004507480A5 JP 2002522827 A JP2002522827 A JP 2002522827A JP 2002522827 A JP2002522827 A JP 2002522827A JP 2004507480 A5 JP2004507480 A5 JP 2004507480A5
- Authority
- JP
- Japan
- Prior art keywords
- bcl
- antisense oligonucleotide
- use according
- oligonucleotide
- deliver
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 108091034117 Oligonucleotide Proteins 0.000 description 18
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 13
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 13
- 239000000074 antisense oligonucleotide Substances 0.000 description 13
- 238000012230 antisense oligonucleotides Methods 0.000 description 13
- 239000012830 cancer therapeutic Substances 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 239000003814 drug Substances 0.000 description 3
- 238000001802 infusion Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22797000P | 2000-08-25 | 2000-08-25 | |
| US23700900P | 2000-09-29 | 2000-09-29 | |
| US09/709,170 US7795232B1 (en) | 2000-08-25 | 2000-11-10 | Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers |
| PCT/US2001/026414 WO2002017852A2 (en) | 2000-08-25 | 2001-08-23 | Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004507480A JP2004507480A (ja) | 2004-03-11 |
| JP2004507480A5 true JP2004507480A5 (https=) | 2008-07-31 |
Family
ID=27397795
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002522827A Withdrawn JP2004507480A (ja) | 2000-08-25 | 2001-08-23 | ｂｃｌ−２アンチセンスオリゴマーを用いてｂｃｌ−２障害を治療する方法 |
Country Status (32)
| Country | Link |
|---|---|
| US (2) | US7795232B1 (https=) |
| EP (2) | EP1313514B1 (https=) |
| JP (1) | JP2004507480A (https=) |
| KR (1) | KR20030034153A (https=) |
| CN (1) | CN1471408A (https=) |
| AP (1) | AP2003002761A0 (https=) |
| AT (1) | ATE432717T1 (https=) |
| AU (2) | AU2001288373B2 (https=) |
| BG (1) | BG107641A (https=) |
| BR (1) | BR0113447A (https=) |
| CA (1) | CA2419480A1 (https=) |
| CY (1) | CY1109340T1 (https=) |
| CZ (1) | CZ301582B6 (https=) |
| DE (1) | DE60138892D1 (https=) |
| DK (1) | DK1313514T3 (https=) |
| DZ (1) | DZ3471A1 (https=) |
| EA (1) | EA005424B1 (https=) |
| EE (1) | EE200300074A (https=) |
| ES (1) | ES2327904T3 (https=) |
| GE (1) | GEP20063934B (https=) |
| HR (1) | HRP20030102A2 (https=) |
| HU (1) | HUP0303125A2 (https=) |
| IL (1) | IL154409A0 (https=) |
| MX (1) | MXPA03001575A (https=) |
| NO (1) | NO20030858L (https=) |
| OA (1) | OA12586A (https=) |
| PL (1) | PL363050A1 (https=) |
| PT (1) | PT1313514E (https=) |
| SK (1) | SK3652003A3 (https=) |
| UA (1) | UA77945C2 (https=) |
| WO (1) | WO2002017852A2 (https=) |
| YU (1) | YU13603A (https=) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5855911A (en) | 1995-08-29 | 1999-01-05 | Board Of Regents, The University Of Texas System | Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides |
| US7309692B1 (en) | 1996-07-08 | 2007-12-18 | Board Of Regents, The University Of Texas System | Inhibition of chronic myelogenous leukemic cell growth by liposomal-antisense oligodeoxy-nucleotides targeting to GRB2 or CRK1 |
| US6977244B2 (en) | 1996-10-04 | 2005-12-20 | Board Of Regents, The University Of Texas Systems | Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides |
| US7704962B1 (en) | 1997-10-03 | 2010-04-27 | Board Of Regents, The University Of Texas System | Small oligonucleotides with anti-tumor activity |
| US7285288B1 (en) | 1997-10-03 | 2007-10-23 | Board Of Regents, The University Of Texas System | Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides |
| CA2992643C (en) | 2002-03-13 | 2019-06-18 | Genomic Health, Inc. | Gene expression profiling in biopsied tumor tissues |
| EP1572970A4 (en) * | 2002-11-14 | 2006-11-15 | Genta Salus Llc | OLIOGONUCLEOTIDES INHIBITORS DIRECTED ON BCL-2 |
| AU2003295598B2 (en) | 2002-11-15 | 2009-12-24 | Genomic Health, Inc. | Gene expression profiling of EGFR positive cancer |
| DE10258677A1 (de) * | 2002-12-13 | 2004-06-24 | Elez, Vera, Dr. | Kombinations-antisense-Oligonukleotid-Krebstherapie |
| US20040231909A1 (en) | 2003-01-15 | 2004-11-25 | Tai-Yang Luh | Motorized vehicle having forward and backward differential structure |
| CA2516553C (en) | 2003-02-20 | 2013-04-16 | Genomic Health, Inc. | Use of intronic rna to measure gene expression |
| EP1640452A4 (en) | 2003-05-30 | 2009-12-23 | Nippon Shinyaku Co Ltd | OLIGOBICATENARY RNA INHIBITING BCL-2 EXPRESSION AND MEDICINAL COMPOSITION CONTAINING THE SAME |
| ES2609234T3 (es) | 2003-06-24 | 2017-04-19 | Genomic Health, Inc. | Predicción de la probabilidad de recidiva de cáncer |
| US7526387B2 (en) | 2003-07-10 | 2009-04-28 | Genomic Health, Inc. | Expression profile algorithm and test for cancer prognosis |
| CA2551267C (en) | 2003-12-23 | 2012-05-01 | Genomic Health, Inc. | Universal amplification of fragmented rna |
| GB0406415D0 (en) * | 2004-03-22 | 2004-04-21 | Inst Of Cancer Res The | Materials and methods for treatment of cancer |
| CA2563074C (en) | 2004-04-09 | 2014-05-20 | Genomic Health, Inc. | Gene expression markers for predicting response to chemotherapy |
| US8815599B2 (en) | 2004-06-01 | 2014-08-26 | Pronai Therapeutics, Inc. | Methods and compositions for the inhibition of gene expression |
| AU2013203202B2 (en) * | 2004-08-26 | 2017-02-16 | Engeneic Molecular Delivery Pty Ltd | Delivering functional nucleic acids to mammalian cells via bacterially derived intact minicells |
| EP2386640B1 (en) | 2004-08-26 | 2015-01-28 | EnGeneIC Molecular Delivery Pty Ltd | Delivering functional nucleic acids to mammalian cells via bacterially-derived, intact minicells |
| JP5020088B2 (ja) | 2004-11-05 | 2012-09-05 | ジェノミック ヘルス， インコーポレイテッド | 遺伝子発現マーカーを使用する、化学療法に対する反応の予測 |
| EP1815014B1 (en) | 2004-11-05 | 2012-03-21 | Genomic Health, Inc. | Molecular indicators of breast cancer prognosis and prediction of treatment response |
| CA2631677C (en) * | 2005-12-01 | 2014-08-12 | Pronai Therapeutics, Inc. | Amphoteric liposome formulation |
| TWI403320B (zh) | 2005-12-16 | 2013-08-01 | Infinity Discovery Inc | 用於抑制ｂｃｌ蛋白和結合夥伴間之交互作用的化合物及方法 |
| CN100368424C (zh) * | 2006-07-21 | 2008-02-13 | 福建金山生物制药股份有限公司 | 抑制肿瘤的反义核苷酸 |
| US20080171718A1 (en) * | 2006-11-08 | 2008-07-17 | Brown Bob D | Methods and Compositions for Treating Cancer Using BCL-2 Antisense Oligomers, Tyrosine Kinase Inhibitors, and Chemotherapeutic Agents |
| DE102007020554A1 (de) * | 2007-04-27 | 2008-10-30 | Henkel Ag & Co. Kgaa | Nukleinsäurehaltige kosmetische und/oder pharmazeutische Zubereitungen zur Behandlung epithelialen Deckgewebes |
| US20090098118A1 (en) | 2007-10-15 | 2009-04-16 | Thomas Friess | Combination therapy of a type ii anti-cd20 antibody with an anti-bcl-2 active agent |
| WO2009071681A2 (en) * | 2007-12-07 | 2009-06-11 | Santaris Pharma A/S | Rna antagonist compounds for the modulation of bcl-2 |
| JP2012509878A (ja) * | 2008-11-21 | 2012-04-26 | アイシス ファーマシューティカルズ， インコーポレーテッド | ドセタキセルおよびアンチセンスオリゴヌクレオチドを含む、抗腫瘍併用療法 |
| AU2010277554B2 (en) | 2009-07-30 | 2015-02-19 | Antisense Pharma Gmbh | Combination of a chemotherapeutic agent and an inhibitor of the TGF-beta system |
| KR101853509B1 (ko) * | 2010-01-06 | 2018-04-30 | 큐알엔에이, 인크. | 췌장 발달 유전자에 대한 천연 안티센스 전사체의 억제에 의한 췌장 발달 유전자와 관련된 질환의 치료 |
| KR20240129101A (ko) * | 2015-07-07 | 2024-08-27 | 제넨테크, 인크. | 항-her2 항체-약물 접합체 및 bcl-2 억제제를 사용한 병용 요법 |
| ES2965461T3 (es) | 2015-08-03 | 2024-04-15 | Biokine Therapeutics Ltd | Inhibidor de CXCR4 para el tratamiento del cáncer |
| CN115515686A (zh) * | 2020-03-18 | 2022-12-23 | 纽约州州立大学研究基金会 | 修饰的短干扰rna组合物及其在癌症治疗中的用途 |
| WO2021231486A1 (en) * | 2020-05-13 | 2021-11-18 | Unity Biotechnology, Inc. | Cancer treatment by senescence induction followed by a senolytic |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5015568A (en) | 1986-07-09 | 1991-05-14 | The Wistar Institute | Diagnostic methods for detecting lymphomas in humans |
| US5202429A (en) | 1986-07-09 | 1993-04-13 | The Wistar Institute | DNA molecules having human BCL-2 gene sequences |
| US5276019A (en) | 1987-03-25 | 1994-01-04 | The United States Of America As Represented By The Department Of Health And Human Services | Inhibitors for replication of retroviruses and for the expression of oncogene products |
| US5098890A (en) | 1988-11-07 | 1992-03-24 | Temple University-Of The Commonwealth System Of Higher Education | Antisence oligonucleotides to c-myb proto-oncogene and uses thereof |
| US5831066A (en) | 1988-12-22 | 1998-11-03 | The Trustees Of The University Of Pennsylvania | Regulation of bcl-2 gene expression |
| US5734033A (en) | 1988-12-22 | 1998-03-31 | The Trustees Of The University Of Pennsylvania | Antisense oligonucleotides inhibiting human bcl-2 gene expression |
| CA2025907A1 (en) | 1989-09-21 | 1991-03-22 | Franklin D. Collins | Method of transporting compositions across the blood brain barrier |
| EP0633934A1 (en) | 1992-04-02 | 1995-01-18 | Imperial Cancer Research Technology Limited | Modified cells and method of treatment |
| JPH08506087A (ja) | 1992-10-21 | 1996-07-02 | テンプル ユニバーシティ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケーション | ガン処置のための抗腫瘍薬とアンチセンスオリゴヌクレオチドの組み合わせ |
| US5550019A (en) | 1993-05-26 | 1996-08-27 | La Jolla Cancer Research Foundation | Methods of identifying compounds which alter apoptosis |
| US5783683A (en) * | 1995-01-10 | 1998-07-21 | Genta Inc. | Antisense oligonucleotides which reduce expression of the FGFRI gene |
| US6214986B1 (en) * | 1998-10-07 | 2001-04-10 | Isis Pharmaceuticals, Inc. | Antisense modulation of bcl-x expression |
-
2000
- 2000-11-10 US US09/709,170 patent/US7795232B1/en not_active Expired - Fee Related
-
2001
- 2001-08-23 UA UA2003032532A patent/UA77945C2/uk unknown
- 2001-08-23 DK DK01968097T patent/DK1313514T3/da active
- 2001-08-23 WO PCT/US2001/026414 patent/WO2002017852A2/en not_active Ceased
- 2001-08-23 ES ES01968097T patent/ES2327904T3/es not_active Expired - Lifetime
- 2001-08-23 PL PL01363050A patent/PL363050A1/xx not_active IP Right Cessation
- 2001-08-23 DZ DZ013471A patent/DZ3471A1/fr active
- 2001-08-23 JP JP2002522827A patent/JP2004507480A/ja not_active Withdrawn
- 2001-08-23 OA OA1200300058A patent/OA12586A/en unknown
- 2001-08-23 MX MXPA03001575A patent/MXPA03001575A/es active IP Right Grant
- 2001-08-23 AU AU2001288373A patent/AU2001288373B2/en not_active Ceased
- 2001-08-23 AT AT01968097T patent/ATE432717T1/de active
- 2001-08-23 CZ CZ20030848A patent/CZ301582B6/cs not_active IP Right Cessation
- 2001-08-23 EA EA200300294A patent/EA005424B1/ru not_active IP Right Cessation
- 2001-08-23 EE EEP200300074A patent/EE200300074A/xx unknown
- 2001-08-23 PT PT01968097T patent/PT1313514E/pt unknown
- 2001-08-23 BR BR0113447-7A patent/BR0113447A/pt not_active IP Right Cessation
- 2001-08-23 KR KR10-2003-7002605A patent/KR20030034153A/ko not_active Ceased
- 2001-08-23 AP APAP/P/2003/002761A patent/AP2003002761A0/en unknown
- 2001-08-23 HR HR20030102A patent/HRP20030102A2/hr not_active Application Discontinuation
- 2001-08-23 EP EP01968097A patent/EP1313514B1/en not_active Expired - Lifetime
- 2001-08-23 IL IL15440901A patent/IL154409A0/xx unknown
- 2001-08-23 AU AU8837301A patent/AU8837301A/xx active Pending
- 2001-08-23 CN CNA018177107A patent/CN1471408A/zh active Pending
- 2001-08-23 SK SK365-2003A patent/SK3652003A3/sk unknown
- 2001-08-23 CA CA002419480A patent/CA2419480A1/en not_active Abandoned
- 2001-08-23 YU YU13603A patent/YU13603A/sh unknown
- 2001-08-23 DE DE60138892T patent/DE60138892D1/de not_active Expired - Lifetime
- 2001-08-23 GE GE5129A patent/GEP20063934B/en unknown
- 2001-08-23 EP EP09007273A patent/EP2135623A1/en not_active Withdrawn
- 2001-08-23 HU HU0303125A patent/HUP0303125A2/hu unknown
-
2003
- 2003-02-24 NO NO20030858A patent/NO20030858L/no unknown
- 2003-03-18 BG BG107641A patent/BG107641A/bg unknown
-
2009
- 2009-09-02 CY CY20091100919T patent/CY1109340T1/el unknown
-
2010
- 2010-04-02 US US12/753,285 patent/US20100216867A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004507480A5 (https=) | ||
| Martin et al. | Controlled-release of opioids for improved pain management | |
| JP2588039B2 (ja) | 段階的な活性物質放出を呈する皮膚経由医療薬として使用されるプラスタ及びその製造方法 | |
| WO2002041878A3 (en) | Titratable dosage transdermal delivery system | |
| JP2004517810A5 (https=) | ||
| GB2316004B (en) | Novel formulations for transdermal delivery of pergolide | |
| CA2240329A1 (en) | Improved delivery of multiple doses of medications | |
| CA2226870A1 (en) | Epidural administration of therapeutic compounds with sustained rate of release | |
| CA2302754A1 (en) | Noribogaine in the treatment of pain and drug addiction | |
| JP2011507860A5 (https=) | ||
| JP2002544231A5 (https=) | ||
| Mercadante et al. | Alternatives to oral opioids for cancer pain | |
| CY2503B1 (en) | Novel formulations for the transdermal administration of fluoxetine acetate and fluoxetine maleate. | |
| JP2002523437A5 (https=) | ||
| CA2401000A1 (en) | Method of treating and diagnosing sleep disordered breathing and means for carrying out the method | |
| JP2008540364A5 (https=) | ||
| JP2003514025A5 (https=) | ||
| CZ289395A3 (en) | Transdermic therapeutic system for administration of serotonin agonists | |
| JP2002530353A5 (https=) | ||
| CA2582452A1 (en) | Pegylated liposomal doxorubicin in combination with ecteinascidin 743 | |
| JP2008517991A5 (https=) | ||
| IL194500A0 (en) | Peptide substance enhancing capillaries resistance, pharmaceutical composition on its base and method of its application | |
| JP2002540148A5 (https=) | ||
| JP2021535163A5 (https=) | ||
| JP5134973B2 (ja) | 医薬の組み合わせでの処置方法およびこれに適する医薬の組み合わせ |